To include your compound in the COVID-19 Resource Center, submit it here.

Modulating mechanism

Why investors backed neurology company Aptinyx’s $70M series B

Aptinyx Inc. parlayed preclinical proof-of-concept data for NYX-2925 into an untranched $70 million series B round that should give the neurology company runway through YE19, when it expects to have data from Phase II trials from NYX-2925

Read the full 371 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers